Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER_GOV × Interventional × daratumumab × Clear all

Phase

Status

Sponsor Class

OTHER 120 INDUSTRY 83 NETWORK 17 NIH 3 OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neoplasms, Plasma Cell 1 Multiple Myeloma 1

Interventions

Cisplatin 38 Capecitabine 34 Gemcitabine 28 Paclitaxel 27 apatinib 26 Carboplatin 26 Oxaliplatin 25 Cyclophosphamide 25 Radiotherapy 24 Irinotecan 24 Drug Therapy 24 Docetaxel 24 tislelizumab 23 Fluorouracil 21 Bevacizumab 21 Nivolumab 16 pembrolizumab 15 Exercise 15 fludarabine 14 Surgical Procedures, Operative 14 camrelizumab 13 S 1 (combination) 13 Metformin 13 Radiation 12 Pemetrexed 10 Control Groups 10 Vinorelbine 9 Standard of Care 9 Leucovorin 9 Letrozole 9

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04065789 2022-01-27

KyDaR

Tel-Aviv Sourasky Medical Center

Phase 2 Completed

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡